Home › Trials › NCT07204275

Povetacicept for people with primary membranous nephropathy

A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

PHASE2; PHASE3 · Vertex Pharmaceuticals Incorporated · NCT07204275

This trial tests whether povetacicept is safe and helps people with primary membranous nephropathy, with tacrolimus listed as an intervention in the protocol.

Quick facts

PhasePHASE2; PHASE3
Study typeInterventional
Enrollment176 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorVertex Pharmaceuticals Incorporated (industry)
Locations93 sites (Montgomery, Alabama and 92 other locations)
Trial IDNCT07204275 on ClinicalTrials.gov

What this trial studies

This Phase 2/3 interventional trial tests the efficacy, safety, and tolerability of povetacicept in adults with biopsy‑confirmed primary membranous nephropathy. Participants must have a historical confirming biopsy or agree to a biopsy during screening, and the protocol also includes tacrolimus as a listed intervention. The study will track clinical endpoints related to disease activity and adverse events over the treatment and follow‑up periods. Vertex Pharmaceuticals is the lead sponsor and the trial is being conducted at selected US renal centers.

Who should consider this trial

Good fit: Adults with biopsy‑confirmed primary membranous nephropathy, or those willing to undergo a screening biopsy, who meet the protocol’s other eligibility criteria and have no hypersensitivity to the study drugs are the expected candidates.

Not a fit: Patients with secondary membranous nephropathy, known hypersensitivity to the investigational product or its excipients, or other exclusionary medical conditions are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, povetacicept could reduce proteinuria and lower the risk of progressive kidney damage in people with primary membranous nephropathy.

How similar studies have performed: Other immunomodulatory treatments such as rituximab and calcineurin inhibitors like tacrolimus have shown benefit in pMN, while povetacicept represents a newer therapeutic approach still being tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

• Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility

Key Exclusion Criteria:

• Hypersensitivity to investigational medicinal product or to any of its excipients

Other protocol defined Inclusion/Exclusion criteria will apply

Where this trial is running

Montgomery, Alabama and 92 other locations

+43 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Primary Membranous Nephropathy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.